NCT02195089View on ClinicalTrials.gov

Efficacy and Safety Study of BLS_ILB_E710c for the Fertile Women With Cervical Intraepithelial Neoplasia(CIN3)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

April 30, 2016

Conditions
Cervical Intraepithelial Neoplasia
Interventions
DRUG

BLS_ILS_E710c 500mg

\- 2 capsules per day for 20 days (week 1,2,4 \& 8)

DRUG

BLS_ILB_710c 1000mg

\- 4 capsules per day for 20 days (week 1,2,4 \& 8)

DRUG

BLS_ILS_E710c 1500mg

\- 6 capsules per day for 8 weeks (week 1,2,4 \& 8)

Trial Locations (5)

152-703

Korea University Guro Hospital, Seoul

700-712

The Dongsan Medical Center of Keimyung University, Daegu

100-380

Kwandong University College of Medicine Cheil Hospital, Seoul

137-701

The Catholic University, Korea Seoul St Mary's Hospital, Seoul

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

BioLeaders Corporation

INDUSTRY